On Jun. 8, 2020, FibroGen announced the initiation of an open-label, randomized, parallel-arm study investigating the efficacy and safety of pamrevlumab versus standard of care in patients with severe coronavirus 2019 (COVID-19) infection at Catholic University of the Sacred Heart in Rome, Italy.